Belatacept
- Generic Name
- Belatacept
- Brand Names
- Nulojix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 706808-37-9
- Unique Ingredient Identifier
- E3B2GI648A
- Background
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of t...
- Indication
For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.
- Associated Conditions
- Kidney Transplant Rejection
- Associated Therapies
- -
Subcutaneous Pharmacokinetics of Belatacept
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 153
- Registration Number
- NCT00569803
- Locations
- 🇺🇸
Ppd Development, Austin, Texas, United States
Belatacept Post Depletional Repopulation to Facilitate Tolerance
- Conditions
- Interventions
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Allan D Kirk, MD, PhD
- Target Recruit Count
- 40
- Registration Number
- NCT00565773
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸The Emory Clinic, Atlanta, Georgia, United States
A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 93
- Registration Number
- NCT00455013
- Locations
- 🇺🇸
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
🇺🇸Denver Nephrology, Pc, Denver, Colorado, United States
🇺🇸University Of Colorado Health Sciences Center, Denver, Colorado, United States
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 173
- Registration Number
- NCT00402168
- Locations
- 🇪🇸
Local Institution, Valencia, Spain
🇩🇪Charite Berlin Mitte, Berlin, Germany
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2017-04-21
- Target Recruit Count
- 5
- Registration Number
- NCT00346151
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 210
- Registration Number
- NCT00279760
- Locations
- 🇬🇧
Local Institution, Leeds, United Kingdom
🇧🇪Local Instiution, Bruxelles, Belgium
Islet Transplantation Using Abatacept
- Conditions
- Interventions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 5
- Registration Number
- NCT00276250
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
- Conditions
- Interventions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 230
- Registration Number
- NCT00035555
- Locations
- 🇺🇸
Medical Univ. of South Carolina, Charleston, South Carolina, United States
🇺🇸Univ. of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.